Over 1 Million ADHD Patches Recalled Due to Liner Defect

Share this content:
Voluntary recall of 6 lots of Daytrana
Voluntary recall of 6 lots of Daytrana

Noven Therapeutics announced a voluntary recall of 6 lots of Daytrana (methylphenidate) due to the patches no longer meeting the release liner removal specification and/or z-statistic. This error can make it difficult for patients and caregivers to remove the liners from the Daytrana patches.

The affected products are as follows:

  • 10mg; Lot #80433; Exp. 08/2017; Quantity: 321,900
  • 15mg; Lot# 80426; Exp. 10/2017; Quantity: 234,960
  • 20mg; Lot #80431; Exp. 08/2017; Quantity: 182,850
  • 30mg; Lot #80442; Exp. 10/2017; Quantity: 117,000
  • 30mg; Lot #80439; Exp. 08/2017; Quantity: 113,160
  • 30mg; Lot #80438; Exp. 08/2017; Quantity: 101,790

Anyone in possession of the recalled Lot# should cease distributing and quarantine the product. Noven is notifying all wholesale and retail customers that may have received the impacted products. 

Daytrana, a central nervous system (CNS) stimulant, is indicated to treat attention deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. It is supplied as 10mg, 15mg, 20mg, and 30mg strength transdermal patches that deliver the medication over 9 hours. 

For more information call (877) 567-7857 or visit Noven.com.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs